A next-generation intranasal delivery platform combining dual antimicrobial mechanisms with sustained mucosal protection—engineered for real-world clinical use.
From rapid pathogen inactivation to prolonged protection, this platform expands beyond single-agent limitations to enable broader, more durable respiratory defence.
The Limitation
Most currently available nasal antimicrobial products rely on single active mechanisms and provide only transient protection. While effective in specific use cases, they face fundamental limitations:
This has resulted in underutilisation outside acute scenarios and limited long-term clinical relevance.
The Opportunity
Upper respiratory environments are exposed to viral, bacterial, and fungal pathogens simultaneously. Yet, no current solution delivers all three requirements:
Sustained antimicrobial presence at the mucosal surface
Broad-spectrum pathogen coverage — viral, bacterial, and fungal
Safe, repeatable use in chronic or preventive settings
This gap represents a significant opportunity to move from episodic treatment → continuous protection.
The Platform
Our platform is built on the co-liberation of two complementary antimicrobial agents, delivered through a controlled-release intranasal system.
NO — Rapid reactive action
I₂ — Persistent broad-spectrum control
Scientific Rationale
Each agent contributes a distinct and validated mode of antimicrobial action. Together, they address the full spectrum of mucosal defence requirements.
Why Sustained Release Matters
Traditional nasal sprays act quickly—but dissipate rapidly. Our platform introduces controlled release kinetics enabling meaningful, prolonged mucosal defence.
Prolonged Residence
Extended mucosal residence time beyond conventional sprays
Reduced Dosing
Lower dosing frequency without compromising coverage
Better Compliance
Improved patient adherence through simpler regimens
Continuous Cover
Uninterrupted antimicrobial activity at the mucosal interface
Particularly critical in
Clinical & Practical Applications
The platform is adaptable across multiple clinical contexts. Unlike single-indication products, this platform supports broad, longitudinal use cases.
Upper respiratory tract infections (URTIs)
Rhinitis and sinusitis
Post-operative infection prevention
Immunocompromised patient protection
Fungal and polymicrobial colonisation
Competitive Positioning
Single-agent products have struggled with narrow scope and short lifecycle, highlighting the need for a more evolved approach.
| Dimension | Conventional NO Spray | This Platform |
|---|---|---|
| Mechanism | Single agent (NO only) | Dual mechanism (NO + Iodine) |
| Duration | Short-lived | Sustained release |
| Spectrum | Primarily antiviral | Antiviral + antibacterial + antifungal |
| Use Case | Pandemic-specific | Broad clinical + preventive |
| Lifecycle | Limited | Long-term clinical relevance |
Platform Advantage
This is not a formulation — it is a delivery platform. It represents a foundation for a new class of intranasal antimicrobial solutions.
Enable co-delivery of complementary active agents within a single system
Control release kinetics precisely at the mucosal interface
Support scalable manufacturing and adaptation across formats
Extend into multiple therapeutic indications beyond initial use
Market Context
Global and Indian markets are witnessing a convergence of trends that position this platform at a critical inflection point.
Rising respiratory disease burden globally
Shift toward preventive and proactive healthcare
Increased adoption of non-invasive delivery systems
Demand for OTC and accessible antimicrobial solutions
Strategic Positioning
The platform enables faster translation from concept to clinic, while maintaining flexibility across indications and partner requirements.
Integration into existing respiratory portfolios
Rapid clinical advancement pathways
Scalable manufacturing and commercialisation
Strategic collaboration with pharmaceutical partners
Get in Touch
Explore how this platform can support your respiratory, infectious disease, and preventive care pipeline.
Discuss your programme